Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 200 of 973 drug-target rows in SSL view, for TSG = PBRM1.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
sunitinib PBRM1 MET 5
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PBRM1 FGFR2 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) PBRM1 FGFR2 4
crizotinib PBRM1 MET 7
crizotinib PBRM1 ALK 7
trastuzumab emtansine PBRM1 ERBB2 7
tucatinib PBRM1 ERBB2 7
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine PBRM1 TYMS 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PBRM1 SMO 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PBRM1 ERBB2 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PBRM1 CDK6 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PBRM1 FGFR3 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PBRM1 MET 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PBRM1 MAP2K1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PBRM1 FGFR2 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PBRM1 BTK 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PBRM1 ALK 3
afatinib PBRM1 ERBB2 3
capecitabine, cisplatin PBRM1 TYMS 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan PBRM1 TOP1 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan PBRM1 FGFR3 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan PBRM1 FGFR2 3
gemcitabine PBRM1 TYMS 3
lurbinectedin, irinotecan PBRM1 TOP1 3
mrtx849, pembrolizumab, cetuximab, afatinib PBRM1 ERBB2 3
pembrolizumab, belzutifan, lenvatinib PBRM1 FGFR3 3
pembrolizumab, belzutifan, lenvatinib PBRM1 FGFR2 3
srf617, gemcitabine, albumin-bound paclitaxel, pembrolizumab PBRM1 TYMS 3
abemaciclib PBRM1 CDK6 7
cabozantinib PBRM1 MET 7
capecitabine PBRM1 TYMS 7
ibrutinib PBRM1 BTK 7
lapatinib PBRM1 ERBB2 7
nintedanib PBRM1 FGFR3 7
nintedanib PBRM1 FGFR2 7
palbociclib PBRM1 CDK6 7
pazopanib PBRM1 FGFR3 7
regorafenib PBRM1 FGFR2 7
sacituzumab govitecan PBRM1 TOP1 7
topotecan PBRM1 TOP1 7
trastuzumab deruxtecan PBRM1 TOP1 5
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin PBRM1 TYMS 2
ab598, zimberelimab, fluorouracil, leucovorin, oxaliplatin PBRM1 TYMS 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel PBRM1 GART 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel PBRM1 TYMS 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel PBRM1 ERBB2 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel PBRM1 FGFR3 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel PBRM1 MET 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel PBRM1 MAP2K1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel PBRM1 FGFR2 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel PBRM1 ALK 2
alectinib, stereotactic radiosurgery PBRM1 ALK 2
alvocidib, paclitaxel PBRM1 CDK6 2
apatinib, irinotecan PBRM1 TOP1 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan PBRM1 TOP1 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan PBRM1 TYMS 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine PBRM1 TOP1 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine PBRM1 TYMS 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 PBRM1 GART 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 PBRM1 TYMS 2
bbi-355, erlotinib, futibatinib PBRM1 FGFR3 2
bbi-355, erlotinib, futibatinib PBRM1 FGFR2 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment PBRM1 TYMS 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment PBRM1 BTK 2
bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis PBRM1 TYMS 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib PBRM1 CDK6 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib PBRM1 MAP2K1 2
biospecimen collection, computed tomography, devimistat, fluorouracil, gemcitabine hydrochloride, hydroxychloroquine, magnetic resonance imaging PBRM1 TYMS 2
biospecimen collection, computed tomography, pemetrexed PBRM1 GART 2
biospecimen collection, computed tomography, pemetrexed PBRM1 TYMS 2
cabozantinib, atezolizumab, cabozantinib, cabozantinib PBRM1 MET 2
capecitabine, carboplatin, epirubicin hydrochloride PBRM1 TYMS 2
capecitabine, docetaxel PBRM1 TYMS 2
capecitabine, irinotecan hydrochloride PBRM1 TYMS 2
capecitabine, oxaliplatin PBRM1 TYMS 2
capecitabine, oxaliplatin, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, quality-of-life assessment, radiation therapy PBRM1 TYMS 2
capecitabine, temozolomide PBRM1 TYMS 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy PBRM1 TYMS 2
cetuximab, cisplatin, fluorouracil, conventional surgery PBRM1 TYMS 2
cetuximab, cisplatin, irinotecan, radiation therapy, surgery PBRM1 TOP1 2
cft1946, trametinib, cetuximab PBRM1 MAP2K1 2
chemotherapy, cisplatin, fluorouracil, low-let electron therapy, low-let photon therapy PBRM1 TYMS 2
cisplatin, fluorouracil, conventional surgery, neoadjuvant therapy, radiation therapy PBRM1 TYMS 2
cisplatin, fluorouracil, iressa, conventional surgery, radiation therapy PBRM1 TYMS 2
cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy PBRM1 TYMS 2
cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy PBRM1 TYMS 2
cisplatin, fluorouracil, surgical procedure, radiation therapy PBRM1 TYMS 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab PBRM1 GART 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab PBRM1 TYMS 2
cobimetinib, mehd7945a PBRM1 MAP2K1 2
durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel PBRM1 TYMS 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab PBRM1 ERBB2 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab PBRM1 CDK6 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib PBRM1 ERBB2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib PBRM1 FGFR2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib PBRM1 ALK 2
erlotinib hydrochloride, oxaliplatin, fluorouracil, radiation therapy, conventional surgery, immunohistochemistry staining method, positron emission tomography, computed tomography, laboratory biomarker analysis, gene expression analysis, fludeoxyglucose f 18 PBRM1 TYMS 2
filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy PBRM1 TYMS 2
filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy PBRM1 TYMS 2
fluorouracil, gemcitabine hydrochloride, leucovorin calcium PBRM1 TYMS 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, pharmacogenomic studies, pharmacological study PBRM1 TYMS 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study PBRM1 TYMS 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study PBRM1 HDAC6 2
fluorouracil, oxaliplatin, conventional surgery, radiation therapy PBRM1 TYMS 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a PBRM1 FGFR3 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a PBRM1 FGFR2 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide PBRM1 TOP1 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide PBRM1 GART 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide PBRM1 TYMS 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib PBRM1 GART 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib PBRM1 TYMS 2
irinotecan, capecitabine PBRM1 TOP1 2
irinotecan, capecitabine PBRM1 TYMS 2
irinotecan, docetaxel PBRM1 TOP1 2
jab-3312, binimetinib, pembrolizumab, sotorasib, osimertinib PBRM1 MAP2K1 2
laboratory biomarker analysis, oxaliplatin, pralatrexate PBRM1 TYMS 2
lenvatinib, pembrolizumab PBRM1 FGFR3 2
lenvatinib, pembrolizumab PBRM1 FGFR2 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate PBRM1 FGFR3 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate PBRM1 FGFR2 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab PBRM1 TOP1 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab PBRM1 GART 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab PBRM1 TYMS 2
m6620, cisplatin, capecitabine, radiotherapy PBRM1 TYMS 2
mirdametinib, bgb-3245 PBRM1 MAP2K1 2
mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed PBRM1 GART 2
mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed PBRM1 TYMS 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a PBRM1 GART 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a PBRM1 TYMS 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a PBRM1 FGFR3 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a PBRM1 FGFR2 2
motexafin gadolinium, radiation therapy PBRM1 RRM2 2
nab-paclitaxel, gemcitabine PBRM1 TYMS 2
nintedanib, pembrolizumab PBRM1 FGFR3 2
nintedanib, pembrolizumab PBRM1 FGFR2 2
nivolumab, ipilimumab, cobimetinib PBRM1 MAP2K1 2
ociperlimab, tislelizumab, pemetrexed, paclitaxel, nab paclitaxel, carboplatin, cisplatin, etoposide, 5fluorouracil, oxaliplatin, capecitabine PBRM1 GART 2
ociperlimab, tislelizumab, pemetrexed, paclitaxel, nab paclitaxel, carboplatin, cisplatin, etoposide, 5fluorouracil, oxaliplatin, capecitabine PBRM1 TYMS 2
olaparib PBRM1 PARP3 2
oleclumab, durvalumab, gemcitabine, nab-paclitaxel, oxaliplatin, folinic acid, 5-fu PBRM1 TYMS 2
oxaliplatin, irinotecan hydrochloride, leucovorin calcium, fluorouracil, laboratory biomarker analysis PBRM1 TYMS 2
pembrolizumab, lenvatinib PBRM1 FGFR3 2
pembrolizumab, lenvatinib PBRM1 FGFR2 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu PBRM1 TYMS 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu PBRM1 FGFR3 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu PBRM1 FGFR2 2
pembrolizumab, paclitaxel, docetaxel, irinotecan PBRM1 TOP1 2
pembrolizumab, sonidegib PBRM1 SMO 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin PBRM1 TYMS 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin PBRM1 FGFR3 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin PBRM1 FGFR2 2
pemetrexed, bevacizumab PBRM1 GART 2
pemetrexed, bevacizumab PBRM1 TYMS 2
pharmacological study, romidepsin PBRM1 HDAC6 2
pralatrexate, docetaxel, fludeoxyglucose f 18, positron emission tomography PBRM1 TYMS 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery PBRM1 FGFR3 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery PBRM1 FGFR2 2
radiotherapy targeted to the primary lesion, radiotherapy targeted to the metastatic lesions, anti-pd-1 monoclonal antibody, trastuzumab, chemotherapy, r0 total/subtotal gastrectomy with d2 lymphadenectomy, metastasectomy, local ablative therapies PBRM1 ERBB2 2
regorafenib, laboratory biomarker analysis PBRM1 FGFR2 2
rubitecan PBRM1 TOP1 2
sar444881, pembrolizumab, cetuximab, carboplatin, pemetrexed PBRM1 GART 2
sar444881, pembrolizumab, cetuximab, carboplatin, pemetrexed PBRM1 TYMS 2
selumetinib, medi4736, tremelimumab PBRM1 MAP2K1 2
sy-5609, fulvestrant, gemcitabine, nab-paclitaxel PBRM1 TYMS 2
tislelizumab, pemetrexed PBRM1 GART 2
tislelizumab, pemetrexed PBRM1 TYMS 2
tivantinib PBRM1 MET 2
trastuzumab PBRM1 ERBB2 2
trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy PBRM1 ERBB2 2
trastuzumab, tipifarnib PBRM1 ERBB2 2
whole brain low dose radiotherapy, pemetrexed, sintilimab, chemotherapy PBRM1 GART 2
whole brain low dose radiotherapy, pemetrexed, sintilimab, chemotherapy PBRM1 TYMS 2
binimetinib PBRM1 MAP2K1 7
erdafitinib PBRM1 FGFR3 7
erdafitinib PBRM1 FGFR2 7
pemetrexed PBRM1 TYMS 7
pemigatinib PBRM1 FGFR3 7
pemigatinib PBRM1 FGFR2 7
ribociclib PBRM1 CDK6 7
romidepsin PBRM1 HDAC6 7
selumetinib PBRM1 MAP2K1 7
trilaciclib PBRM1 CDK6 7
18f-fluoromisonidazole, cediranib maleate, laboratory biomarker analysis, olaparib, positron emission tomography PBRM1 PARP3 1
2b3-101, trastuzumab, 2b3-101 60 mg/m2 every 4 weeks, 2b3-101 50 mg/m2 every 3 weeks PBRM1 ERBB2 1
3-dimensional conformal radiation therapy, bevacizumab, cisplatin, fluorouracil, intensity-modulated radiation therapy PBRM1 TYMS 1
3-dimensional conformal radiation therapy, biospecimen collection, capecitabine, chemotherapy, computed tomography, erlotinib hydrochloride, fluorouracil, gemcitabine hydrochloride, intensity-modulated radiation therapy, magnetic resonance imaging, quality-of-life assessment, x-ray imaging PBRM1 TYMS 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat PBRM1 HDAC6 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat PBRM1 HDAC6 1
3-dimensional conformal radiation therapy, motexafin gadolinium, temozolomide PBRM1 RRM2 1
4-dimensional computed tomography, fluorouracil, gemcitabine hydrochloride, laboratory biomarker analysis, leucovorin calcium, nelfinavir mesylate, oregovomab, stereotactic body radiation therapy, therapeutic conventional surgery PBRM1 TYMS 1
5 fluorouracil, leucovorin, irinotecan, oxaliplatin PBRM1 TOP1 1
5-fluorouracil (5-fu), leucovorin, oxaliplatin, atezolizumab, cobimetinib, ramucirumab, paclitaxel, pegylated recombinant human hyaluronidase (pegph20), bl-8040, linagliptin, atezolizumab, cobimetinib, cisplatin, tiragolumab, 5-fluorouracil (5-fu) PBRM1 MAP2K1 1
5-fu, leucovorin, docetaxel, oxaliplatin (flot), trastuzumab, post-operative treatment trastuzumab mono therapy PBRM1 ERBB2 1
6,8-bis(benzylthio)octanoic acid, oxaliplatin, leucovorin calcium, irinotecan hydrochloride, fluorouracil, laboratory biomarker analysis PBRM1 TYMS 1
7-hydroxystaurosporine, fluorouracil PBRM1 TYMS 1
9-ing-41, gemcitabine - 21 day cycle, doxorubicin., lomustine, carboplatin., nab paclitaxel., paclitaxel., gemcitabine - 28 day cycle, irinotecan PBRM1 TOP1 1
9-ing-41, retifanlimab, gemcitabine, abraxane PBRM1 TYMS 1
abbv-400, budigalimab, fluorouracil, leucovorin, oxaliplatin PBRM1 TYMS 1
abemaciclib, abemaciclib PBRM1 CDK6 1
abemaciclib, bevacizumab PBRM1 CDK6 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.